Molecular characteristics of papillary thyroid carcinomas without BRAF mutation or RET/PTC rearrangement: Relationship with clinico-pathological features

Endocrine-Related Cancer

Volumn 16, Issue 2, 2009, Pages 467-481

  Durand, Stéphanie ^a,b   Ferraro Peyret, Carole ^a,c   Joufre, Mireille ^c   Chave, Annie ^c   Borson Chazot, Françoise ^a,b   Selmi Ruby, Samia ^a,b   Rousset, Bernard ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ LYON 1   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CHITINASE; CHITINASE 3; CYSTATIN; CYTOKERATIN 19; DUAL SPECIFICITY PHOSPHATASE 6; FIBRONECTIN; GALECTIN 3; HISTONE ACETYLTRANSFERASE PCAF; INHIBITOR OF DIFFERENTIATION 3; LAMININ; LAMININ BETA 3; MIDKINE; PROTEIN BCL 2; PROTEIN PATCHED; PROTEIN RET; PROTEIN S; SERINE PROTEINASE; SERINE PROTEINASE 23; SERINE PROTEINASE INHIBITOR; SYNDECAN 4; THYROGLOBULIN; THYROID PEROXIDASE; THYROXINE DEIODINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN TYROSINE KINASE; RET PTC FUSION ONCOPROTEINS, HUMAN; RET-PTC FUSION ONCOPROTEINS, HUMAN; TUMOR MARKER;

ARTICLE; CANCER GRADING; CONTROLLED STUDY; DOWN REGULATION; ENZYME REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MUTATION; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MICROARRAY ANALYSIS; POLYMERASE CHAIN REACTION; PROGNOSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; THYROID PAPILLARY CARCINOMA; UPREGULATION; ADULT; AGED; CHILD; DNA MICROARRAY; FEMALE; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; PAPILLARY CARCINOMA; PATHOLOGY; THYROID TUMOR; WESTERN BLOTTING;

ADULT; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, PAPILLARY; CHILD; FEMALE; GENE EXPRESSION PROFILING; GENE REARRANGEMENT; HUMANS; MIDDLE AGED; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS, FUSION; POLYMERASE CHAIN REACTION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 67650477285     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-08-0081     Document Type: Article

References (46)

1. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW & Nikiforov YE 2006 Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. American Journal of Surgical Pathology 30 216-222.
2. Aldred MA, Huang Y, Liyanarachchi S, Pellegata NS, Gimm O, Jhiang S, Davuluri RV, de la Chapelle A & Eng C 2004 Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. Journal of Clinical Oncology 22 3531-3539.
3. Bongarzone I, Vigneri P, Mariani L, Collini P, Pilotti S & Pierotti MA 1998 RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clinical Cancer Research 4 223-228.
4. Chomczynski P & Sacchi N 1987 Single-step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction. Analytical Biochemistry 162 156-159.
5. De Deken X, Wang D, Many MC, Costagliola S, Libert F, Vassart G, Dumont JE & Miot F 2000 Cloning of two human thyroid cDNAs encoding new members of the NADPH oxidase family. Journal of Biological Chemistry 275 23227-23233.
6. Durand S, Ferraro-Peyret C, Selmi-Ruby S, Paulin C, El Atifi M, Berger F, Berger-Dutrieux N, Decaussin M, Peix JL, Bournaud C et al. 2008 Evaluation of gene expression profiles in thyroid nodule biopsy material to diagnose thyroid cancer. Journal of Clinical Endocrinology and Metabolism 93 1195-1202.
7. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A et al. 2007 BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. Journal of Clinical Endocrinology and Metabolism 92 2840-2843.
8. Eisen MB, Spellman PT, Brown PO & Botstein D 1998 Cluster analysis and display of genome-wide expression patterns. PNAS 95 14863-14868.
9. Finley DJ, Arora N, Zhu B, Gallagher L & Fahey TJ 3rd 2004 Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. Journal of Clinical Endocrinology and Metabolism 89 3214-3223.
10. Finn SP, Smyth P, Cahill S, Streck C, O'Regan EM, Flavin R, Sherlock J, Howells D, Henfrey R, Cullen M et al. 2007 Expression microarray analysis of papillary thyroid carcinoma and benign thyroid tissue: emphasis on the follicular variant and potential markers of malignancy. Virchows Archive 450 249-260.
11. Fusco A, Grieco M, Santoro M, Berlingieri MT, Pilotti S, Pierotti MA, Della Porta G & Vecchio G 1987 A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature 328 170-172.
12. Van Gelder RN, von Zastrow ME, Yool A, Dement WC, Barchas JD & Eberwine JH 1990 Amplified RNA synthesized from limited quantities of heterogeneous cDNA. PNAS 87 1663-1667.
13. Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K et al. 2005 Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24 6646-6656.
14. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A & Vecchio G 1990 PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60 557-563.
15. Griffith OL, Melck A, Jones SJ & Wiseman SM 2006 Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. Journal of Clinical Oncology 24 5043-5051.
16. Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K, LiVolsi V, Frankel W, Kloos RT, Eng C et al. 2001 Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. PNAS 98 15044-15049.
17. Jarry A, Masson D, Cassagnau E, Parois S, Laboisse C & Denis MG 2004 Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E. Molecular and Cellular Probes 18 349-352.
18. Jarzab B, Wiench M, Fujarewicz K, Simek K, Jarzab M, Oczko-Wojciechowska M, Wloch J, Czarniecka A, Chmielik E, Lange D et al. 2005 Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Research 65 1587-1597.
19. Jhiang SM 2000 The RET proto-oncogene in human cancers. Oncogene 19 5590-5597.
20. Knauf JA, Kuroda H, Basu S & Fagin JA 2003 RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene 22 4406-4412.
21. Kondo T, Ezzat S & Asa SL 2006 Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature Review Cancer 6 292-306.
22. Lacroix L, Nocera M, Mian C, Caillou B, Virion A, Dupuy C, Filetti S, Bidart JM & Schlumberger M 2001 Expression of nicotinamide adenine dinucleotide phosphate oxidase flavoprotein DUOX genes and proteins in human papillary and follicular thyroid carcinomas. Thyroid 11 1017-1023.
23. Lam AK, Montone KT, Nolan KA & Livolsi VA 1998 Ret oncogene activation in papillary thyroid carcinoma: prevalence and implication on the histological parameters. Human Pathology 29 565-568.
24. Liu D, Hu S, Hou P, Jiang D, Condouris S & Xing M 2007 Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clinical Cancer Research 13 1341-1349.
25. Lubitz CC, Ugras SK, Kazam JJ, Zhu B, Scognamiglio T, Chen YT & Fahey TJ 3rd 2006 Microarray analysis of thyroid nodule fine-needle aspirates accurately classifies benign and malignant lesions. Journal of Molecular Diagnostics 8 490-498 quiz 528.
26. Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, Materazzi G, Elisei R, Santoro M, Miccoli P et al. 2007 Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 92 4085-4090.
27. Mazzanti C, Zeiger MA, Costouros NG, Umbricht C, Westra WH, Smith D, Somervell H, Bevilacqua G, Alexander HR & Libutti SK 2004 Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Research 64 2898-2903.
28. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M et al. 2005 The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. Journal of Clinical Investigation 115 1068-1081.
29. Mesa C Jr, Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, Knauf JA, Weber GF & Fagin JA 2006 Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Research 66 6521-6529.
30. Mitsutake N, Knauf JA, Mitsutake S, Mesa C Jr, Zhang L & Fagin JA 2005 Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Research 65 2465-2473.
31. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T & Yamashita S 2003 Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. Journal of Clinical Endocrinology and Metabolism 88 4393-4397.
32. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A et al. 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. Journal of Clinical Endocrinology and Metabolism 88 5399-5404.
33. Nikiforova MN, Ciampi R, Salvatore G, Santoro M, Gandhi M, Knauf JA, Thomas GA, Jeremiah S, Bogdanova TI, Tronko MD et al. 2004 Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Letters 209 1-6.
34. Porra V, Ferraro-Peyret C, Durand C, Selmi-Ruby S, Giroud H, Berger-Dutrieux N, Decaussin M, Peix JL, Bournaud C, Orgiazzi J et al. 2005 Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 90 3028-3035.
35. Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M & Santisteban P 2006 The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocrine-Related Cancer 13 257-269.
36. Santoro M, Carlomagno F, Hay ID, Herrmann MA, Grieco M, Melillo R, Pierotti MA, Bongarzone I, Della Porta G, Berger N et al. 1992 Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. Journal of Clinical Investigation 89 1517-1522.
37. Santoro M, Dathan NA, Berlingieri MT, Bongarzone I, Paulin C, Grieco M, Pierotti MA, Vecchio G & Fusco A 1994 Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene 9 509-516.
38. Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, Chiappetta G, Carcangiu ML & Fusco A 1998 RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clinical Cancer Research 4 287-294.
39. Trouttet-Masson S, Selmi-Ruby S, Bernier-Valentin F, Porra V, Berger-Dutrieux N, Decaussin M, Peix JL, Perrin A, Bournaud C, Orgiazzi J, Borson-Chazot F, Franc B & Rousset B 2004 Evidence for transcriptional and posttranscriptional alterations of the sodium/iodide symporter expression in hypofunctional benign and malignant thyroid tumors. American Journal of Pathology 165 25-34.
40. Tusher VG, Tibshirani R & Chu G 2001 Significance analysis of microarrays applied to the ionizing radiation response. PNAS 98 5116-5121.
41. De Vita G, Zannini M, Cirafici AM, Melillo RM, Di Lauro R, Fusco A & Santoro M 1998 Expression of the RET/PTC1 oncogene impairs the activity of TTF-1 and Pax-8 thyroid transcription factors. Cell Growth & Differentiation 9 97-103.
42. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D et al. 2004 Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116 855-867.
43. Wasenius VM, Hemmer S, Kettunen E, Knuutila S, Franssila K & Joensuu H 2003 Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clinical Cancer Research 9 68-75.
44. Xing M 2005 BRAF mutation in thyroid cancer. Endocrine-Related Cancer 12 245-262.
45. Xing M 2007 BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocrine Reviews 28 742-762.
46. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G et al. 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 90 6373-6379.